Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Duchenne muscular dystrophy (DMD) is a severe, X-linked genetic disorder causing progressive muscle degeneration.
• Current clinical outcome measures for DMD therapies have long lead times, hindering drug development.
• Validated molecular biomarkers in biofluids are needed to monitor disease progression and optimize drug dosing.

Purpose of the Study:

• To review promising molecular biomarkers for Duchenne muscular dystrophy identified in muscle tissue, primarily from animal models.
• To focus on biomarkers related to myonecrosis, inflammation, and oxidative stress in DMD.
• To discuss the translation of these biomarkers for clinical use in DMD patients.

Main Methods:

• Review of scientific literature on DMD biomarkers.
• Focus on studies identifying biomarkers in muscle, blood, and urine.
• Analysis of biomarkers associated with myonecrosis, inflammation (e.g., neutrophils), and oxidative stress (e.g., protein thiol oxidation).

Main Results:

• Numerous candidate biomarkers for dystrophic muscle have been identified, particularly those linked to myonecrosis, inflammation, and oxidative stress.
• Data from dystrophic animal models show promise for biomarkers in muscle, blood, and urine.
• Early myonecrosis and regeneration events are key pathological features associated with potential biomarkers.

Conclusions:

• Molecular biomarkers are essential for accelerating the development and clinical testing of Duchenne muscular dystrophy therapies.
• Translating biomarkers from animal models to human clinical trials presents challenges but is critical for success.
• Further validation studies are needed to establish robust biomarkers for monitoring DMD progression and treatment efficacy.